Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Incyte(INCY) Businesswire·2024-02-05 21:46WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® (tafasitamab-cxix) and outside of the U.S. as Minjuvi® (tafasitamab). “This new agreement with MorphoSys provides Incyte with exclusive global rights to tafasitamab and full control over its development and ...